TMU4142

  1. Home
  2. Wiki

TMU4142
Clinical data
Other namesTMU-4142
Drug classSerotonin 5-HT1A receptor biased agonist
ATC code
  • None
Chemical and physical data
FormulaC23H30N3O4
Molar mass412.510 g·mol−1
3D model (JSmol)
  • O[C](CNCCCN1C(=O)CC2(CCCC2)CC1=O)COc3cccc4[nH]ccc34
  • InChI=1S/C23H30N3O4/c27-17(16-30-20-6-3-5-19-18(20)7-11-25-19)15-24-10-4-12-26-21(28)13-23(14-22(26)29)8-1-2-9-23/h3,5-7,11,24-25,27H,1-2,4,8-10,12-16H2
  • Key:NJZRIWWCDITGNS-UHFFFAOYSA-N

TMU4142 is a potent and selective serotonin 5-HT1A receptor biased agonist.[1] It is a preferential near-full agonist of the GoA pathway with weak agonism of the Gi3 pathway and little or no β-arrestin2 recruitment.[1]

Presynaptic serotonin 5-HT1A autoreceptors predominantly signal via the Gi3 pathway in the dorsal raphe nucleus (DRN) and are associated with feedback inhibition that may hamper therapeutic effects, whereas postsynaptic serotonin 5-HT1A heteroreceptors couple mainly to Go pathways in hippocampal and cortical areas and are thought to mediate antidepressant-like effects.[1] As such, TMU4142 is a selective postsynaptic serotonin 5-HT1A receptor agonist with the potential for greater antidepressant activity than other serotonin 5-HT1A receptor agonists, such as 8-OH-DPAT, buspirone, gepirone, F-15599 (NLX-101), and vilazodone, among others.[1] On the other hand, the Gz pathway is thought to be involved in anxiolytic-like effects.[1] Analogously to TMU4142, pindolol is a moderate-efficacy partial agonist of the Go pathways but a very weak partial agonist or antagonist of Gi pathways.[1]

TMU4142 produces rapid antidepressant-like effects in rodents without modifying serotonin levels or neuronal firing rates in the DRN.[1] This is in contrast to other serotonin 5-HT1A receptor agonists like buspirone and F-13714, which are strong presynaptic serotonin 5-HT1A receptor agonists and reduce DRN serotonin levels and neuronal firing rates.[1] It is also in contrast to serotonin reuptake inhibitors, which work by elevating serotonin levels.[1]

TMU4142 was first described in the scientific literature by Chunyu Wang and colleagues in 2025.[1] It is a combined derivative or analogue of pindolol and azapirones with improved pharmacological properties such as selectivity, biased agonism, and activational efficacy.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i j k Wang C, Zhang N, Shao Y, Li T, Zhang M, Gao M, et al. (November 2025). "Pathway-selective 5-HT1AR agonist as a rapid antidepressant strategy". Cell. doi:10.1016/j.cell.2025.10.022. PMID 41232528.